NCT05518032 2024-09-26
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Roswell Park Cancer Institute
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT04119830 2022-02-08
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT03182894 2018-08-28
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 1/2 Withdrawn